This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Global Liver Cancer Diagnostic Market Size, Share & Trends Analysis Report (2019-2025): CAGR of 8.1% is Projected - ResearchAndMarkets.com

March 6, 2019

DUBLIN--(BUSINESS WIRE)--Mar 6, 2019--The “Liver Cancer Diagnostic Market Size, Share & Trends Analysis Report By Screening Type (Biopsy, Endoscopy, Laboratory Tests, Imaging), By Region (North America, APAC, Europe), And Segment Forecasts, 2019 - 2025” report has been added to ResearchAndMarkets.com’s offering.

The global liver cancer diagnostics market size is expected to reach USD 15.4 billion by 2025. The market is projected to expand at a CAGR of 8.1% over the estimated time period.

Rise in disease incidence coupled with growing demand for novel diagnosis products are thrusting the growth of the market. Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer in adults. It is among the common causes of death in people with liver cirrhosis and the third-leading cause of cancer deaths across the globe. Poor survival rate and lack of therapies has made this disease a crucial health issue worldwide.

Government and some global health organizations are undertaking initiatives to raise awareness regarding liver cancer through various campaigns. These programs aim to create awareness about signs, symptoms, and complications associated with carcinomas. High costs associated with cancer treatments compared to other diseases have led to increasingly rigid treatment guidelines for expensive drugs and diagnostic tests across various markets.

For instance, the Affordable Care Act, designed to improve quality of healthcare and reduce the cost associated with it. This act covers reimbursement for cancer diagnosis and treatment up to a certain extent. Governments in other countries are also taking efforts to overcome challenges, such as cost and access to cancer care.

Such efforts and insurance policies that cover cost of diagnosis and treatment of carcinomas are supporting market growth. Newer techniques developed for hepatocellular carcinoma render both liver transplant, as well as surgical resection, more effective and safer. Several etiological factors of HCC such as hepatitis infection and cirrhosis are modifiable and thus present a strong prospect to reduce disease mortality by preventive strategies.

Key players and medical institutions are focusing on the development of advanced tests for HCC diagnosis. These factors along with high unmet needs are expected to propel the growth of liver cancer diagnostics market through the forecast period.

Further key findings from the study suggest:

  • Increasing awareness about liver cancer across the globe is expected to be the major factor driving the market growth
  • Laboratory tests emerged as the largest segment owing to increased demand for effective diagnostic tests for HCC
  • Oncofetal and Glucoprotein antigens accounted for the largest share in biomarkers segment
  • North America led the global liver cancer diagnostic market in 2017 and will maintain the dominance in future on account of rising awareness about early diagnosis and demand for novel diagnostic tests in the region
  • Illumina, Inc.; Qiagen; F. Hoffmann-La Roche Ltd.; Siemens Healthcare GmbH; and Thermo Fisher Scientific are some of the leading industry participants

Topics Covered

Chapter 1 Methodology and Scope

1.1 Research Methodology

1.1.1 Information Procurement

1.2 Information or Data Analysis

1.3 Research Scope and Assumptions

1.4 List to Data Sources

Chapter 2 Executive Summary

2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

3.1 Market Segmentation

Chapter 4 Industry Outlook

4.1 Market Variable Analysis

4.1.1 Failure rate of conventional diagnosis

4.1.2 Early detection leading to reduced healthcare costs

4.2 Market Restraint Analysis

4.2.1 High risk of radiation exposure and stringent regulatory guidelines

4.2.2 High cost and unmet needs

Chapter 5 Business Environment Analysis

5.1 SWOT Analysis; by factor (political & legal, economic and technological)

5.2 Porter’s five forces analysis

Chapter 6 Liver Cancer Diagnostics Market: Screening Type Business Analysis

6.1 Liver Cancer Diagnostics: Type Movement Analysis

6.2 Laboratory Tests

6.3 Biomarker Tests

6.4 Imaging

6.5 Endoscopy

6.6 Biopsy

6.7 Others

Chapter 7 Liver Cancer Diagnostics Market Regional Business Analysis

7.1 Liver Cancer Diagnostics Market: Regional Movement Analysis

7.2 North America

7.3 Europe

7.4 Asia Pacific

7.5 Latin America

7.6 Middle East & Africa

Chapter 8 Company Profiles

8.1 Abbott Laboratories

8.2 Roche Diagnostics

8.3 Qiagen

8.4 Siemens Healthineers

8.5 Thermo Fischer Scientific Inc.

8.6 Hologic

8.7 Becton, Dickinson and Company

8.8 Sirtex Medical Ltd.

8.9 Koninklijke Philips N.V.

8.10 Illumina, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/4fhr44/global_liver?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190306005290/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Diagnostics



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/06/2019 04:48 AM/DISC: 03/06/2019 04:48 AM